Key result
Bay U3405 reduces platelet deposition by ~33% versus control in a baboon model.
Why the study?
The study aimed to determine if Bay U3405, a thromboxane A2-receptor antagonist, could inhibit arterial thrombosis in vivo.
Does Bay U3405 reduce platelet-dependent thrombus formation in a baboon model of arterial thrombosis?
Comparison
Bolus injection of Bay U3405 vs control studies in same baboons
Design
Preclinical in vivo thrombosis model study
Follow-up
2 hours
Authors
Loading...
Bay U3405 reduced thrombus formation in this model; leaves open whether TxA2 antagonism prevents clinical arterial thrombosis.
Does Bay U3405 reduce platelet-dependent thrombus formation in a baboon model of arterial thrombosis?
In a baboon model, the thromboxane A2-receptor antagonist Bay U3405 significantly reduced acute platelet-dependent arterial thrombus formation.
Kotzé et al. (1993) studied Arterial thrombosis (n=6). Bay U3405 vs. Control studies done in the same baboons was evaluated on Platelet deposition (maximum thrombus formation). In a baboon model, a bolus injection of Bay U3405 reduced platelet deposition by 33 +/- 14% at 2 hours compared to control studies in the same animals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: